Normal growth of nephrotic children during long-term alternate-day prednisone therapy.
Statural growth has been evaluated in 20 prepubertal nephrotic children who received alternate-day prednisone therapy for a year at least. Bone age was assessed in 16 of these children after 1-4 years of therapy. During the follow-up 12 children showed variations in height standard deviation score (SDs) below 0.5, 7 gained more than 0.5 SDs and 1 lost 0.5 SDs. Bone age fell within the normal range for chronological age in all the children studied. On the while alternate-day prednisone therapy does not affect statural growth and bone maturation of children with lipoid nephrosis.
D001846:Bone Development / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006128:Growth / Q000187:drug effects*; D006801:Humans; D007223:Infant; D008297:Male; D009402:Nephrosis, Lipoid / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage*; D013997:Time Factors
D011241:Prednisone